Search research articles
Contact Us
Filters
Showing results (231-240 of 244) with videos related to
Page
of 25
Sort By:
Journal of Alzheimer'S Disease : JAD
|
August 4, 2020
Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance
Steve Pedrini, Eugene Hone, Veer B Gupta, et al.
Pathogens & Immunity
|
September 20, 2021
Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level
Shay Leary, Silvana Gaudieri, Matthew D Parker, et al.
Scientific Reports
|
May 10, 2018
Evidence of CD4<sup>+</sup> T cell-mediated immune pressure on the Hepatitis C virus genome
Michaela Lucas, Pooja Deshpande, Ian James, et al.
Biorxiv : the Preprint Server for Biology
|
April 21, 2021
Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level
Shay Leary, Silvana Gaudieri, Matthew D Parker, et al.
The Journal of Allergy and Clinical Immunology
|
February 19, 2019
HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms
Katherine C Konvinse, Jason A Trubiano, Rebecca Pavlos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2017
<sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Frederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580
James G Conway, Brad McDonald, Janet Parham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Investigational New Drugs
|
January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.
Nature
|
December 14, 2004
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA
Photini Kiepiela, Alasdair J Leslie, Isobella Honeyborne, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 244) with videos related to
Sort By:
Page
of 25
Journal of Alzheimer'S Disease : JAD
|
August 4, 2020
Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance
Steve Pedrini, Eugene Hone, Veer B Gupta, et al.
Pathogens & Immunity
|
September 20, 2021
Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level
Shay Leary, Silvana Gaudieri, Matthew D Parker, et al.
Scientific Reports
|
May 10, 2018
Evidence of CD4<sup>+</sup> T cell-mediated immune pressure on the Hepatitis C virus genome
Michaela Lucas, Pooja Deshpande, Ian James, et al.
Biorxiv : the Preprint Server for Biology
|
April 21, 2021
Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level
Shay Leary, Silvana Gaudieri, Matthew D Parker, et al.
The Journal of Allergy and Clinical Immunology
|
February 19, 2019
HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms
Katherine C Konvinse, Jason A Trubiano, Rebecca Pavlos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2017
<sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Frederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580
James G Conway, Brad McDonald, Janet Parham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.
Investigational New Drugs
|
January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.
Nature
|
December 14, 2004
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA
Photini Kiepiela, Alasdair J Leslie, Isobella Honeyborne, et al.
Page
of 25